Region: United States
Advanced Solid Tumors

The OncoExTra® report

Uncover what matters most in an actionable, easy-to-interpret report.

The most relevant information. Always.

As oncology care evolves, new genomic variants are constantly coming to light. The OncoExTra report has it covered. Because the test investigates all protein-coding DNA genes and the entire RNA transcriptome, any of today's findings will be relevant as new therapies become available in the future.1

Download a sample report:

Lung
Breast
Colorectal
Bladder
 

Streamlined, actionable insights for timely decision-making

For patients with advanced cancer, timely knowledge is crucial. The OncoExTra report highlights the most clinically relevant information first, to support prompt, point-of-care discussions between oncologists and their patients, leading to shared treatment decisions.1*

Report

*Select immunohistochemical (IHC) panels and single stains are offered as an optional add-on. IHC not currently available in New York State.
 †The OncoExTra test is not an FDA-cleared or -approved IVD device or companion diagnostic for the referenced biomarkers and FDA-approved therapies.

1
Discover variants and fusions associated with FDA-approved treatments†

A snapshot of variants and fusions delivers an ultra-comprehensive genomic picture, while providing information about treatment options

 
2
See tumor mutational burden and microsatellite instability

Immuno-oncology signatures (TMB/MSI) support truly individualized decisions

 
3
Find clinical trial options for your patient

Pairing your patients’ genomic results with potential clinical trials helps provide more treatment opportunities

 
3
Add on IHC panels*

17 IHC tests are available, including:

  • 3 PD-L1 clones
  • Preselected tumor-specific panels
  • Single IHC stains: PD-L1 (SP263, 22C3, SP142), ALK, HER2, MLH1, PD1, PTEN, AR, IDO, MSH2, PMS2, TRKpan, ER, MET, MSH6, PR

Download the guide

ASCO® recommends fusion testing when:

there are FDA-approved fusion-targeted therapies for that specific disease, as well as testing for other fusions if no other variants are identified on panel-based DNA sequencing2

Actionable results within 14 days of sample submission receipt1

Results provided via fax or through our secure, intuitive online Provider Hub

Go to Provider Hub

Expert report consultation at your convenience

Our medical team brings 20+ years of experience in genomic oncology—and is available to help with interpreting test results

Contact Medical Team

IHC, immunohistochemistry; MSI, microsatellite instability; TMB, tumor mutational burden.